US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Latest News about XNAS:TNXP
Recent news which mentions XNAS:TNXP
Tonix Pharmaceuticals Nears Market Entry with Tonmya for Fibromyalgia Management
June 11, 2024
Tags
Tonix Pharmaceuticals
XNAS:TNXP
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defense funded trial
February 28, 2024
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results in Webinar Presentation
February 28, 2024
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals announces key topline data from 2nd Phase 3 Clinical Trial of TNX-102 SL
January 02, 2024
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals shared details of IND clearance for Phase 2 trial of TNX-2900
December 12, 2023
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program
November 20, 2023
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of Fibromyalgia
November 20, 2023
Tags
Tonix Pharmaceuticals
XNAS:TNXP
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals releases positive results from Proof-Of-Concept Study on TNX-102 SL
September 19, 2023
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals begins Phase 1 trial of TNX-1500 in healthy participants
August 28, 2023
Tags
Tonix Pharmaceuticals
XNAS:TNXP
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals begins Phase 1 trial of TNX-1500 in healthy participants
August 21, 2023
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals fibromyalgia study published in American College of Rheumatology
June 28, 2023
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals shares breakthrough of TNX-601 ER study on patients with depression
May 31, 2023
Tags
Tonix Pharmaceuticals
XNAS:TNXP
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation
April 24, 2023
Tags
XNAS:TNXP
Tonix Pharmaceuticals
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio
February 24, 2023
Tags
Tonix Pharmaceuticals
XNAS:TNXP
From
TheNewswire.com - RSS (Media)
Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies
February 02, 2023
Tags
Tonix Pharmaceuticals
XNAS:TNXP
From
TheNewswire.com - RSS (Media)
Tonix CEO Calls for New Class of Covid-19 Pre-Exposure and Therapeutic Antibodies for High-Risk Populations
January 24, 2023
Tickers
TNXP
Tags
Tonix Pharmaceuticals Holding Corp/
XNAS:TNXP
From
TheNewswire.com - RSS (Media)